CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 500 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
MBQ-167
CAS:<p>MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively).</p>Formula:C22H18N4Purity:98.07% - 99.52%Color and Shape:SolidMolecular weight:338.41Simurosertib
CAS:<p>Simurosertib (TAK-931) is a selective and ATP-competitive cell division cycle 7 kinase inhibitor (IC50: <0.3 nM).</p>Formula:C17H19N5OSPurity:99.93% - 99.93%Color and Shape:SolidMolecular weight:341.43Amantadine hydrochloride
CAS:<p>Amantadine hydrochloride (CI-719) is an antiviral that is used in the prophylactic or symptomatic treatment of influenza A and Parkinson disease.</p>Formula:C10H18ClNPurity:99.98%Color and Shape:Solid CrystallineMolecular weight:187.71CDK12/13-IN-2
<p>CDK12/13-IN-2 (Compound 24) is a covalent inhibitor of CDK12 and CDK13, exhibiting IC50 values of 15.5 nM and 12.2 nM, respectively. It effectively inhibits the proliferation of breast cancer cells and can be utilized in the research of triple-negative breast cancer.</p>Formula:C24H22FN7O2Color and Shape:SolidMolecular weight:459.48(E/Z)-THZ1 2HCl
CAS:<p>THZ1 2HCl: selective CDK7 allosteric inhibitor, IC50 3.2 nM, hinders cancer cell growth.</p>Formula:C31H30Cl3N7O2Purity:99.51%Color and Shape:SolidMolecular weight:638.98JH-XVI-178
CAS:<p>JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.</p>Formula:C22H22ClN7OColor and Shape:SolidMolecular weight:435.92CDK4/6-IN-23
<p>CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.</p>Formula:C32H34FN7O4Color and Shape:SolidMolecular weight:599.655LL-K8-22
<p>LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.</p>Formula:C37H43N5OColor and Shape:SolidMolecular weight:573.77(1S,3R,5R)-PIM447 dihydrochloride
<p>(1S,3R,5R)-PIM447 (dihydrochloride) an inhibitor of PIM(IC50 of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3).</p>Formula:C24H25Cl2F3N4OPurity:98%Color and Shape:SolidMolecular weight:513.38PROTAC CDK9 degrader 4
CAS:<p>PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.</p>Formula:C43H56N10O5Color and Shape:SolidMolecular weight:792.97CDK9 inhibitor HH1
CAS:<p>CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.</p>Formula:C13H15N3OSPurity:99.92%Color and Shape:SolidMolecular weight:261.34dCeMM3
CAS:<p>dCeMM3 is a glue degrader that induces ubiquitination and degradation of cyclin K by promoting CDK12-cyclin K interaction with CRL4B ligase.</p>Formula:C14H11ClN4OSPurity:98.48% - 99.41%Color and Shape:SolidMolecular weight:318.78CDK2-IN-43
<p>CDK2-IN-43 (Compound 3a) is a CDK2-cyclin E2 inhibitor with an IC50 value of 6.0 nM. It is applicable to cancer research.</p>Formula:C19H27N7OColor and Shape:SolidMolecular weight:369.464BSJ-04-132
<p>Selective Cdk4 degrader. Degrades Cdk4 in Molt-4 cells, with no effect on Cdk6 levels. Displays cereblon-dependent degradation.</p>Color and Shape:LiquidJH-XI-10-02
CAS:<p>JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.</p>Formula:C53H69N5O9Purity:98%Color and Shape:SolidMolecular weight:920.161[pSer2, pSer5, pSer7]-CTD TFA
<p>Substrate '[pSer2, pSer5, pSer7]-CTD (TFA)' for CDK7 phosphorylates RNA Pol II CTD at ser2, 5, 7.</p>Formula:C98H138F3N21O39Purity:98%Color and Shape:SolidMolecular weight:2291.25IV-361
CAS:<p>IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1</p>Formula:C23H32FN5O2SiColor and Shape:SolidMolecular weight:457.625CDK7-IN-7
CAS:<p>CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).</p>Formula:C20H20BrF3N6O2Color and Shape:SolidMolecular weight:513.319EGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Formula:C49H32N12O2S2Purity:98%Color and Shape:SolidMolecular weight:884.99CDK9 ligand 3
CAS:<p>CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.</p>Formula:C18H18BrCl2N5O3Color and Shape:SolidMolecular weight:503.177
